- Scientific content at ASCRS related to EVO ICL™ doubles with 44
posters and presentations
- STAAR is leading a comprehensive clinical education program
including a lunch symposium, multiple in-booth and offsite events,
as well as online through the launch of STAAR University
- EVO ICL advocate, Will Levis, Tennessee Titans Quarterback,
sharing his EVO ICL experience in the STAAR booth Saturday, 11:30
a.m. – 1:00 p.m. ET
- Previewing Stella™, STAAR’s new ordering and planning platform,
launching Spring/Summer ‘24
STAAR Surgical Company (NASDAQ: STAA), a leading developer,
manufacturer and marketer of the EVO family of Implantable
Collamer® Lenses (EVO ICL) for myopia, astigmatism and presbyopia,
comes to the American Society of Cataract and Refractive Surgery
Annual Meeting (ASCRS) in Boston from April 5-8, 2024, fresh off
the achievement of a new commercial milestone: three million lenses
sold. Furthering the momentum behind its flagship product, EVO ICL,
the company is proud to showcase the clinical, practice and
innovation advantages through a series of posters, presentations
and educational programs. STAAR Surgical can be found at Booth 527
and additional ASCRS event information is available at
https://ascrs.org/annual-meeting.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20240402599401/en/
(Graphic: Business Wire)
“EVO ICL is the next logical step in refractive innovation.
While adoption of any new technology takes time, EVO ICL’s adoption
rate has been steadily rising since launch – achieving market
leadership in key markets – and proving the viability of a global
paradigm shift in refractive surgery that both expands the channel,
and grows patient adoption within it,” said Tom Frinzi, President
and CEO of STAAR Surgical. “At STAAR, we’re focused on raising
awareness of the benefits of corneal-preserving technology, then
training surgeons to be both clinically confident when they
implant, and commercially confident as they integrate EVO ICL into
their practices. Our ASCRS presence was designed to deliver both
clinical and commercial confidence for surgeons ready to shape the
future of refractive surgery.”
Data, Educational Programming and Resources Supporting
Clinical Confidence
New clinical data during the scientific session continues to
support EVO ICL patient advantages and provide insights to guide
successful implementation in practice. On Saturday, April 6, 2024,
a study showcasing “Outcomes of 229 Consecutive EVO Implantable
Collamer Lenses in a US Based Single Center Study” will be
presented by Taj Nasser, MD, and co-authors. This is the largest US
commercial use outcomes paper to-date following FDA approval of
EVO/EVO+. Also of note is a new diagnostics comparison study by J.
Morgan Micheletti, MD, ABO, FACS, which demonstrates a large-scale
analysis of measurement variables between eight different readily
available diagnostic devices used in the evaluation of refractive
surgery patients.
STAAR is also supporting clinical confidence through the
following educational programs and events:
- Lunch Symposium: Modernizing Refractive Surgery –
Expanding Options for Myopic Patients with EVO ICL, Friday, April
5, 11:30 a.m. – 1:00 p.m. Room I53ABC
- Navigating Early Experience with EVO ICL, in-booth,
Saturday, April 6, 10:00 a.m. Booth 527
- All You Wanted to Know about EVO ICL but Were Afraid
to Ask, a roundtable discussion hosted at two times, Saturday,
April 6, 12:00 p.m. and Sunday, April 7, 12:00 p.m. Booth 527
- Discovering EVO ICL in My Early Refractive Training,
Booth 527, Saturday, April 6, 3:30 p.m.
Registration for in-booth discussions is available at:
https://www.surveymonkey.com/r/STAAR-Booth Registration for
roundtable discussions is available at:
https://www.surveymonkey.com/r/STAAR-table
Expanding Clinical Affairs Resources, Online and In-Booth at
ASCRS
STAAR advances clinical excellence with the launch of STAAR
University, a new website to support clinical confidence. The
website offers surgeons access to a wealth of resources, including
publications, key clinical outcomes data, and more. The STAAR booth
will also feature a first-ever Medical Affairs Information Desk,
serving as a hub for surgeons seeking medical inquiry, literature
support, and specialized assistance for Investigator-Initiated
Research inquiries and Independent Medical Education inquiries.
Commercial Confidence through Practice Support
STAAR is leading the way in investment to grow the refractive
surgery channel, and supporting surgeons who are ready to grow
their business, modernize their practice and maximize their
comprehensive refractive offering. Several opportunities to
experience STAAR’s practice advantage on display at ASCRS,
include:
- Meet & Greet with Tennessee Titans Quarterback and EVO
ICL advocate, Will Levis, at the STAAR Booth 527, from 11:30
a.m. – 1:00 p.m. on Saturday, April 6
- In-booth discussion on Patient-Centered Communications:
Practical Strategies for Discussing EVO ICL, Saturday, April 6,
1:30 p.m. Booth 527
- In-booth discussion on Patient Acquisition: Best Practices
and Behaviors, Sunday, April 7, 10:00 a.m. Booth 527
Innovation Advantage
STAAR will offer an in-booth preview of Stella, STAAR’s latest
innovation in ordering, designed to streamline and elevate the EVO
ICL ordering and planning process. Appointments for Stella previews
are available at
https://calendly.com/staar-surgical/stella-training
For more information about EVO Implantable Collamer® Lenses,
visit https://evoicl.com. Connect with us on social media at:
Facebook, Instagram, and LinkedIn.
About STAAR Surgical
STAAR, which has been dedicated solely to ophthalmic surgery for
over 40 years, designs, develops, manufactures and markets
implantable lenses for the eye. These lenses are intended to
provide visual freedom for patients, lessening or eliminating the
reliance on glasses or contact lenses. All of these lenses are
foldable, which permits the surgeon to insert them through a small
incision. STAAR’s lens used in refractive surgery is called an
Implantable Collamer® Lens or “ICL,” which includes the EVO ICL™
product line. More than 3,000,000 ICLs have been sold to date and
STAAR markets these lenses in over 75 countries. To learn more
about the ICL go to: EVOICL.com. Headquartered in Lake Forest, CA,
the company operates manufacturing and packaging facilities in
Aliso Viejo, CA, Monrovia, CA, and Nidau, Switzerland. For more
information, please visit the Company’s website at
www.staar.com.
Important Safety Information for EVO ICL
The EVO Visian ICL lens is intended to correct/reduce
nearsightedness between -3.0 D up to -20.0 D and treat astigmatism
from 1.0 D to 4.0 D. If you have nearsightedness within these
ranges, EVO Visian ICL surgery may improve your distance vision
without eyeglasses or contact lenses. Because the EVO Visian ICL
corrects for distance vision, it does not eliminate the need for
reading glasses, you may require them at some point, even if you
have never worn them before. Since implantation of the EVO Visian
ICL is a surgical procedure, before considering EVO Visian ICL
surgery you should have a complete eye examination and talk with
your eye care professional about EVO Visian ICL surgery, especially
the potential benefits, risks, and complications. You should
discuss the time needed for healing after surgery. Complications,
although rare, may include need for additional surgical procedures,
inflammation, loss of cells from the back surface of the cornea,
increase in eye pressure, and cataracts. You should NOT have EVO
Visian ICL surgery if your doctor determines that 1) the shape of
your eye is not appropriate, 2) you do not meet the minimum
endothelial cell density for your age at the time of implantation,
3) you have moderate to severe glaucoma, 4) your vision is not
stable; or 5) if you are pregnant or nursing.
For additional information with potential benefits, risks and
complications please visit evoicl.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240402599401/en/
Media Allie Holmes Vice President, Marketing (626)
303-7902, Ext. 9683 aholmes@staar.com
Investors Brian Moore Vice President, Investor Relations
and Corporate Development (626) 303-7902, Ext. 3023
bmoore@staar.com
Grafico Azioni STAAR Surgical (NASDAQ:STAA)
Storico
Da Gen 2025 a Feb 2025
Grafico Azioni STAAR Surgical (NASDAQ:STAA)
Storico
Da Feb 2024 a Feb 2025
